|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents.
|
10496535 |
1999 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of fascin-1 and MAP17 was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 127 patients with resectable breast cancer.
|
31273628 |
2019 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression of fascin-1 and MAP17 was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 127 patients with resectable breast cancer.
|
31273628 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
High MAP17 expression was positively correlated with gender, distant metastasis, early recurrence (≤ 2 year), and serum alpha-fetoprotein (all <i>p</i> < 0.05).
|
29190940 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer.
|
25837675 |
2015 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer.
|
25837675 |
2015 |
|
Thyroid carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Quantitative RT-PCR showed that HS6ST2, COL1A1, F2RL1, LEPREL1, PDZK1, and PDZK1IP1 are overexpressed in thyroid carcinoma samples compared with normal thyroids.
|
24848707 |
2014 |
|
Thyroid carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In addition, we show that aberrant promoter hypomethylation-associated overexpression of MAP17 might promote tumor growth in thyroid cancer.
|
23666970 |
2013 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Real-time qRT-PCR validation experiment of LCN2 and PDZK1IP1 showed a consistent up-regulation in the metastasis group.
|
22419659 |
2012 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors.
|
30119639 |
2018 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy.
|
30119639 |
2018 |
|
Rectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In the present manuscript, we examined the values of MAP17 and pH2AX as surrogate biomarkers of the response in rectal tumors.
|
30250642 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas.
|
30119639 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer.
|
29616128 |
2018 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer.
|
29616128 |
2018 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer.
|
29616128 |
2018 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Paroxysmal AF comparing to permanent AF and SR individuals had higher estimated SPAP (56 versus 48 versus 47 mmHg, <i>p</i> = 0.01) and shorter ACT (58 versus 65 versus 70 ms, <i>p</i> = 0.04).
|
28280732 |
2017 |
|
Psoriasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry confirms local inflammation, mainly CD45<sup>+</sup> cells, at the site of expression of MAP17, at least in tumors, Crohn's and psoriasis.
|
29228712 |
2017 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cox regression analysis indicated MAP17 was an independent prognostic factor for DFS (HR, 1.710; 95% CI, 1.156-2.449, <i>p</i> = 0.012) and OS (HR, 1.743; 95% CI, 1.152-2.639, <i>p</i> = 0.009) in HCC.
|
29190940 |
2017 |
|
Idiopathic pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
(1) Compared with the control group, the PAH group had lower body mass and weight increment, and relative to the latter, 5-ASA-treated groups had larger body mass and weight increment except for groups 5-ASA-150 and 5-ASA-200 and greater overall survival rates; (2) SPAP, DPAP, MPAP, and RVHI in 5-ASA-treated groups, except for MPAP and RVHI in 5-ASA-200 group, were lower than those in the PAH group; (3) compared with the PAH group, Nur77 expression in the pulmonary arteries of 5-ASA-treated groups was increased; and (4) expression of inflammatory mediators (NF-κB p65) was lower, while that of IκBα was higher in the pulmonary arteries of 5-ASA-treated groups and control group than that in the PAH group (all P < 0.05).
|
28213866 |
2017 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differential gene expression analysis demonstrated significant upregulation of PDZK1IP1, EEF1A2 and RPL41 (ENSG00000279483) genes in the iCCA samples when compared with the matched para‑tumor samples.
|
27082702 |
2016 |
|
Primary cholangiocarcinoma of intrahepatic biliary tract
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differential gene expression analysis demonstrated significant upregulation of PDZK1IP1, EEF1A2 and RPL41 (ENSG00000279483) genes in the iCCA samples when compared with the matched para‑tumor samples.
|
27082702 |
2016 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors.
|
25837675 |
2015 |
|
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors.
|
25837675 |
2015 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors.
|
25837675 |
2015 |